A detailed history of National Bank Of Canada transactions in Novo Nordisk A S stock. As of the latest transaction made, National Bank Of Canada holds 279,028 shares of NVO stock, worth $24.5 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
279,028
Previous 279,028 -0.0%
Holding current value
$24.5 Million
Previous $33.2 Million -0.0%
% of portfolio
0.05%
Previous 0.05%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$119.07 - $145.42 $2.1 Million - $2.57 Million
17,641 Added 6.75%
279,028 $33.2 Million
Q2 2024

Aug 02, 2024

SELL
$122.71 - $146.91 $22.5 Million - $26.9 Million
-183,264 Reduced 41.22%
261,387 $37.3 Million
Q1 2024

May 13, 2024

BUY
$102.11 - $135.92 $27 Million - $35.9 Million
264,155 Added 146.35%
444,651 $57.1 Million
Q4 2023

Feb 06, 2024

SELL
$87.78 - $105.45 $481,385 - $578,287
-5,484 Reduced 2.95%
180,496 $18.7 Million
Q3 2023

Oct 10, 2023

BUY
$90.94 - $199.54 $8.87 Million - $19.5 Million
97,586 Added 110.4%
185,980 $16.9 Million
Q2 2023

Jul 26, 2023

BUY
$155.98 - $172.65 $1.29 Million - $1.42 Million
8,250 Added 10.29%
88,394 $14.3 Million
Q1 2023

Apr 12, 2023

SELL
$132.34 - $159.14 $5.24 Million - $6.3 Million
-39,584 Reduced 33.06%
80,144 $12.8 Million
Q4 2022

Jan 24, 2023

BUY
$102.55 - $135.33 $3.45 Million - $4.55 Million
33,656 Added 39.1%
119,728 $0
Q3 2022

Oct 13, 2022

BUY
$95.28 - $116.93 $61,169 - $75,069
642 Added 0.75%
86,072 $8.62 Million
Q2 2022

Jul 28, 2022

SELL
$103.24 - $121.81 $1.68 Million - $1.98 Million
-16,281 Reduced 16.01%
85,430 $9.51 Million
Q1 2022

May 05, 2022

BUY
$93.1 - $112.54 $1.03 Million - $1.24 Million
11,048 Added 12.19%
101,711 $11.6 Million
Q4 2021

Jan 24, 2022

BUY
$95.88 - $117.08 $8.69 Million - $10.6 Million
90,663 New
90,663 $10 Million

Others Institutions Holding NVO

About NOVO NORDISK A S


  • Ticker NVO
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,257,289,984
  • Market Cap $198B
  • Description
  • Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...
More about NVO
Track This Portfolio

Track National Bank Of Canada Portfolio

Follow National Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of National Bank Of Canada , based on Form 13F filings with the SEC.

News

Stay updated on National Bank Of Canada with notifications on news.